Brief: Silexion To Begin Phase 2/3 Pancreatic Cancer Clinical Trial In Q2 2026
25/11/2025 16:46
Nov 25 (Reuters) - Silexion Therapeutics Corp SLXN.O: SILEXION THERAPEUTICS SUCCESSFULLY COMPLETES TOXICOLOGY STUDIES FOR SIL204, NEXT-GENERATION RNA SILENCING THERAPY, AHEAD OF PHASE 2/3 CLINICAL TRIAL IN PANCREATIC CANCER SILEXION THERAPEUTICS CORP - PHASE 2/3 CLINICAL TRIAL IN PANCREATIC CANCER SET FOR Q2 2026 Source text: ID:nGNX6sntSh Further company coverage: SLXN.O ((Reuters.Briefs@thomsonreuters.com;))